^
Association details:
| Biomarker: | VTCN1 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | felmetatug vedotin (SGN-B7H4V) (Microtubule inhibitor, B7-H4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Published date:
10/04/2023
Excerpt:
In an immunocompetent murine B7-H4-expressing tumor model, SGN-B7H4V drove robust antitumor activity as a monotherapy that was enhanced when combined with an anti-PD-1 agent...The immune checkpoint ligand B7-H4 is a promising molecular target expressed by multiple solid tumors. SGN-B7H4V demonstrates robust antitumor activity in preclinical models through multiple potential mechanisms.
Secondary therapy:
PD1 inhibitor
DOI:
10.1136/jitc-2023-007572
Source:
Title:
Abstract 1281: SGN-B7H4V shows immunomodulatory activity through induction of immunogenic cell death
Published date:
06/15/2022
Excerpt:
In vitro, tumor cells treated with SGN-B7H4V showed several hallmarks of immunogenic cell death, including calreticulin exposure and release of ATP. In vivo, treatment of B7-H4-expressing tumors with SGN-B7H4V led to immune changes in the tumor microenvironment, including recruitment of macrophages and T cells. Finally, SGN-B7H4V drove robust, curative activity in an immunocompetent tumor model as a monotherapy and paired well with an anti-PD1 agent.
Secondary therapy:
PD1 inhibitor
DOI:
10.1158/1538-7445.AM2022-1281
